TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28205322
Drug: Exenatide QWS-AI
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QWS-AI 2.0 mg
Study: 21372444
Drug: LAC2E (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + clarithromycin 200 mg bid + ecabet sodium 2 g bid for 1 week)
Study: 21372444
Drug: LA2E (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + ecabet sodium 2 g bid for 2 weeks)
Study: 19141090
Drug: Adjunctive devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive devices during percutaneous coronary intervention (PCI)
Study: 14979943
Drug: One per
Normalized name: Just One Per Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: One per cent silver nitrate gel
Study: 14979943
Drug: 0.1 per
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 per cent silver nitrate gel
Study: 10929023
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation (ASCT) after high-dose chemotherapy (BEAM regimen)
Study: 9382536
Drug: Neoadjuvant intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant intra-arterial infusion chemotherapy (Epirubicin on Days 1, 3, 5, 7 + MPA 1,200 mg)
Study: 9382536
Drug: Adjuvant intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intravenous chemotherapy
Study: 8452102
Drug: Toremifene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (20 to 200 mg/day)
Study: 31874283
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 5 μg
Study: 31874283
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 2.5 μg
Study: 12063159
Drug: Sertraline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline alone (50-200 mg)
Study: 16263177
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus IPT
Study: 23983248
Drug: Brain natriuretic
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain natriuretic peptide >100 pg/mL
Study: 12628864
Drug: Nasal CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal CPAP with oral device
Study: 9118652
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 10 micrograms/kg/min
Study: 7681656
Drug: Poly(I):poly(C12U) 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly(I):poly(C12U) 600 mg
Study: 7681656
Drug: Poly(I):poly(C12U) 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly(I):poly(C12U) 200 mg
Study: 25444805
Drug: 2009-H1N1 vaccine
Normalized name: influenza A virus A/California/7/2009 (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009-H1N1 vaccine + Placebo
Study: 25444805
Drug: H1N1 vaccine
Normalized name: Influenza H1N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1N1 vaccine + Placebo + IIV3
Study: 3914368
Drug: Fluocinonide ointment
Normalized name: Fluocinonide Ointment
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide ointment 0.05%
Study: 11239618
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 microg vaginally, administered at home 24 hours after mifepristone.
Study: 11239618
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 microg vaginally, administered at home 48 hours after mifepristone.
Study: 11239618
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 microg vaginally, administered at home 72 hours after mifepristone.
Study: 1627763
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta administered subcutaneously (s.c.) with two doses per week
Study: 1627763
Drug: Subcutaneous dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dosing two or three times a week
Study: 31544230
Drug: Two consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consecutive doses of 24 mg intravenous dexamethasone (DXM)
Study: 28525303
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with diode laser 830 nm
Study: 26019694
Drug: Garlic (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (900 mg powdered garlic)
Study: 24316697
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the same dosage as Bromelain
Study: 19720922
Drug: Plerixafor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (240 microg/kg) plus G-CSF (10 microg/kg)
Study: 19720922
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus G-CSF (10 microg/kg)
Study: 8326972
Drug: Pilocarpine 10
Normalized name: pilocarpine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 10 mg orally three times a day for 12 weeks
Study: 3551671
Drug: Saline nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline nebulization (2 ml saline t.i.d.)
Study: 3551671
Drug: Bromhexine nebulization
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine nebulization (2 ml bromhexine, 2 mg/ml t.i.d.)
Study: 21268547
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg (E250)
Study: 21268547
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg (E500)
Study: 21268547
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg (M)
Study: 21268547
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (Z)
Study: 12576259
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg per day
Study: 10738641
Drug: Vincamine reference
Normalized name: vincamine
DrugBank: Vincamine (DB13374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincamine reference product (60 mg single dose)
Study: 8646829
Drug: Twice-a-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day regimen
Study: 8646829
Drug: Doses taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses taken at prescribed intervals
Study: 2056895
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment at 0.0 W.cm‐2
Study: 2056895
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment at 1.5 W.cm‐2, pulsed 50%
Study: 2056895
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment at 1.5 W.cm‐2, continuous
Study: 6405876
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acebutolol combined with 12.5 mg hydrochlorothiazide
Study: 6405876
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of hydrochlorothiazide
Study: 26929219
Drug: Tocilizumab infusions
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab infusions at 4-week intervals (3 infusions total) followed by oral prednisone from weeks 12 to 24 (0.15 mg/kg if PMR-AS ≤10 and 0.30 mg/kg otherwise)
Study: 26929219
Drug: Tocilizumab infusions
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab infusions
Study: 23019949
Drug: Jing'an Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jing'an Oral Liquid (JOL)
Study: 17935230
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg/day from day 7 to day 21 and 1 mg/kg/day from day 22 to day 28)
Study: 11895960
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (2 x 10^8 CFU)
Study: 7637364
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy plus dipyridamole (225 to 400 mg per day)
Study: 17158523
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy alone
Study: 7637364
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy plus dipyridamole
Study: 6218101
Drug: antibiotics selected
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotics selected on the basis of bacteriological results (Regimen D)
Study: 16941337
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment (HAART initiated within 2 weeks of seroconversion)
Study: 16941337
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (HAART initiated between 2 weeks and 6 months after seroconversion)
Study: 27498099
Drug: Monthly module
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly module group
Study: 27498099
Drug: Weekly module
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly module group
Study: 19940233
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg plus Rabeprazole 10 mg
Study: 19940233
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg (once daily)
Study: 12576938
Drug: Filgrastim (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (300 microg/day) administered as a 30-min intravenous infusion for 5 days or until white blood cell count reached >75.0 x 10(9) cells/L
Study: 12576938
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapy with filgrastim
Study: 10389953
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg intravenous (IV) ketorolac
Study: 3729509
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution
Study: 6849731
Drug: Chlordiazepoxide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (25 mg)
Study: 23524015
Drug: FP/S 500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/S 500/100 μg/day Diskus®
Study: 20975611
Drug: No angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: No angiotensin-converting enzyme inhibitor group
Study: 19118243
Drug: High-dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B vitamin supplementation (5 mg folic acid + 0.4 mg vitamin B12 + 50 mg vitamin B6)
Study: 18854539
Drug: High-dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B vitamin supplementation
Study: 17159081
Drug: Aliskiren +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren + Hydrochlorothiazide (150 mg + 25 mg)
Study: 15120684
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam prophylaxis
Study: 15120684
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral prophylaxis (Control)
Study: 11100761
Drug: Low-dose nitroglycerin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nitroglycerin (3 microg per kg heart weight per min)
Study: 11100761
Drug: Bolus nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus nitroglycerin (2 mg into the aortic root)
Study: 18503141
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nitrendipine
Study: 8249556
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nitrendipine
Study: 3698063
Drug: Rociverine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rociverine (20 mg)
Study: 15002318
Drug: berlition 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: berlition 300 oral
Study: 2186623
Drug: 0.5% podofilox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podofilox solution
Study: 29958027
Drug: Multimicronutrient syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimicronutrient syrup
Study: 28435031
Drug: Metered-dose-inhaler with
Normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose-inhaler with AeroChamber Vent (MDI-AV) with humidification
Study: 28435031
Drug: Metered-dose-inhaler with
Normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose-inhaler with AeroChamber Vent (MDI-AV) without humidification
Study: 22441962
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (submaximal treadmill walking, 30 min daily, 3 times a week for 6 weeks)
Study: 21309695
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg every morning or two times per day as glycinate)
Study: 21309695
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg b.i.d.)
Study: 31827626
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg/day)
Study: 16433205
Drug: Celecoxib (CE)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (CE) 200 mg
Study: 9016418
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for 85-year-old patients
Study: 9016418
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for patients with bleeding risk factors
Study: 9016418
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription by physicians with favorable opinions
Study: 9016418
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription despite good experience and favorable opinions
Study: 1611986
Drug: Midazolam (Dormicum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (Dormicum 7.5 mg)
Study: 24450992
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CDSMP + PDA (n = 99)
Study: 22834932
Drug: Sham-laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-laser treatment + SRP
Study: 18681820
Drug: Sertraline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (up to 50 or 100 mg/day)
Study: 11006058
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive and estrogen replacement therapy users
Study: 29198064
Drug: Tablet (200-μg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (200-μg)
Study: 27981529
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d regular oral intake of aspirin
Study: 24239210
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment (paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab)
Study: 29855294
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment
Study: 2690739
Drug: Mother's expressed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother's expressed milk with banked milk supplement
Study: 1131298
Drug: Freshly extracted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freshly extracted juice of 50 g of garlic
Study: 27586512
Drug: Dexmedetomidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine and analgesics for 72 hours after abdominal operations
Study: 27586512
Drug: Only analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only analgesics
Study: 26884660
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia (ketamine-propofol) only (Control)
Study: 23406536
Drug: Deflazacort (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (1 mg/kg/day in month one, 1 mg/kg every 2nd day during months two to six)
Study: 21931864
Drug: Intraduodenal pea
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal pea protein administration (250 mg/kg bodyweight in 0.4 ml/kg bodyweight of water)
Study: 21931864
Drug: Intraduodenal pea
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal pea protein administration
Study: 21931864
Drug: Placebo (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.4 ml/kg bodyweight of water)
Study: 21931864
Drug: Oral pea
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pea protein administration
Study: 20029895
Drug: Pattern-mixture zero-inflated
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pattern-mixture zero-inflated model with compound Poisson random effects
Study: 15272628
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution (placebo)
Study: 15272628
Drug: Intravenous cytoflavin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cytoflavin
Study: 11232022
Drug: Transdermal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal administration of 100 microgram/day estradiol (E(2)) for 2 days
Study: 1425532
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (individual counselling)
Study: 1425532
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (group therapy)
Study: 1425532
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (school health care setting)
Study: 4011126
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (500 mg, 3 times daily for 3 months)
Study: 29866199
Drug: Prescription hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription hydration plan (PHP)
Study: 19398690
Drug: Electronic health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic health record enhancement (smoking status icons, tobacco treatment reminders, Tobacco Smart Form)
Study: 11786563
Drug: Adenosine 5'‐triphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 5'‐triphosphate (ATP) infusion (10 intravenous, 30‐hour infusions every 2 to 4 weeks)
Study: 15565568
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (30 mg/d orally)
Study: 2905632
Drug: Neuroleptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic therapy in schizophrenics with affective heredity
Study: 2905632
Drug: Neuroleptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic therapy in schizophrenics with schizophrenic heredity
Study: 22171201
Drug: Exposure, Relaxation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure, Relaxation, and Rescripting Therapy (ERRT)
Study: 25320361
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg/day
Study: 18283233
Drug: Cefuroxime IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime IV 750 mg tid for 3 days followed by cefuroxime-axetil PO 500 mg bid for 7 days
Study: 10378132
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of azithromycin as a single dose
Study: 10378132
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of azithromycin once daily for 3 days
Study: 6630540
Drug: Self-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered cognitive therapy (RET)
Study: 6630540
Drug: Self-administered attention
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered attention placebo condition (Logo-therapy)
Study: 7610222
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control condition
Study: 15747805
Drug: Computer-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based treatment focusing on phonological and morphological structure of Dutch words
Study: 15747805
Drug: Computer-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based treatment
Study: 12125829
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention program (8 weeks)
Study: 10220188
Drug: Pneumatic foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic foot compression combined with low-molecular-weight heparin for approximately 7 days after surgery
Study: 10220188
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (control group)
Study: 8570764
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (5 mg) pretreatment
Study: 8759084
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aspirin
Study: 31267502
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine without booster
Study: 31267502
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine with booster
Study: 25885011
Drug: augmented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: augmented treatment (stimulant + parent training + risperidone)